Eli Lilly and Co (XSGO:LLYCL)
CLP 767490 -8430 (-1.09%) Market Cap: 728.77 Tn Enterprise Value: 755.05 Tn PE Ratio: 86.20 PB Ratio: 50.39 GF Score: 64/100

Eli Lilly and Co at SVB Leerink Global Healthcare Conference (Virtual) Transcript

Feb 24, 2021 / 06:40PM GMT
Geoffrey Craig Porges
SVB Leerink LLC, Research Division - Director of Therapeutics Research & Diversified Biopharma and Senior Research Analyst

Good afternoon. Welcome, everybody, to the afternoon session of our global healthcare conference this year. I'm delighted to welcome Lilly to our presentation and virtual -- on a virtual basis. Lilly is represented by Ilya Yuffa, who's President of Lilly Bio-Medicines, And Ilya is responsible for all the Phase III immunology, pain and related programs as well as for the commercial responsibility for this very broad portfolio. So Ilya, thank you for joining us today.

Ilya Yuffa
Eli Lilly and Company - Senior VP & President of Lilly Bio-Medicines

Great to be here with you, Geoff. Thank you very much.

Questions & Answers

Geoffrey Craig Porges
SVB Leerink LLC, Research Division - Director of Therapeutics Research & Diversified Biopharma and Senior Research Analyst

So this is a pretty big portfolio, and there's a lot going on. Obviously, your COVID

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot